Search

Displaying results 1581 - 1590 of 1777 in total
  1. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.

  2. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF

  3. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).

  4. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.

  5. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects.

  6. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.

  7. Drug

    Diazepam

    go.drugbank.com/drugs/DB00829
    ApprovedIllicitInvestigationalVet approved

    diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA

  8. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.

  9. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    [A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis.

  10. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior